{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:39:53Z","timestamp":1786736393774,"version":"build-2736575974"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Cancer"],"published-print":{"date-parts":[[2017]]},"DOI":"10.4103\/ijc.ijc_374_17","type":"journal-article","created":{"date-parts":[[2019,6,17]],"date-time":"2019-06-17T05:14:22Z","timestamp":1560748462000},"page":"631","source":"Crossref","is-referenced-by-count":3,"title":["Safety and antitumor activity of arsenic trioxide plus infusional 5-fluorouracil, leucovorin, and irinotecan as second-line chemotherapy for refractory metastatic colorectal cancer: A pilot study from South India"],"prefix":"10.4103","volume":"54","author":[{"given":"Tamojit","family":"Chaudhuri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KC","family":"Lakshmaiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GovindK","family":"Babu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dasappa","family":"Lokanatha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LinuAbraham","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MC","family":"Suresh Babu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AH","family":"Rudresha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KN","family":"Lokesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LK","family":"Rajeev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0019-509X.237893-1","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1002\/cncr.20154","article-title":"New systemic frontline treatment for metastatic colorectal carcinoma","author":"Braun","year":"2004","journal-title":"Cancer"},{"key":"key-10.4103\/0019-509X.237893-2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1023\/A:1008200825886","article-title":"Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study","author":"D\u00edaz-Rubio","year":"1998","journal-title":"Ann Oncol"},{"key":"key-10.4103\/0019-509X.237893-3","first-page":"2938","article-title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer","author":"de","year":"2000","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0019-509X.237893-4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","article-title":"FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study","author":"Tournigand","year":"2004","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0019-509X.237893-5","first-page":"16S","article-title":"MRC Clinical Trial Unit: Fluorouracil, oxaliplatin and CPT-11 (irinotecan) use and sequencing (MRC FOCUS).A 2135-patients randomized trial in advanced colorectal cancer (ACRC)","author":"Seymour","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"key":"key-10.4103\/0019-509X.237893-6","doi-asserted-by":"crossref","unstructured":"Pluzanska A, Mainwaring P, Cassidy J, Utracka-Hutka B, Zalucki J, Glynne-Jones R, et al. Final results of a randomized phase III study evaluating the addition for oxaliplatin first-line to 5-FU followed by irinotecan at progression in advanced colorectal cancer (Life study). Proc Am Soc Clin Oncol 2005;23:16S. [Abstr 3517].","DOI":"10.1200\/jco.2005.23.16_suppl.3517"},{"key":"key-10.4103\/0019-509X.237893-7","doi-asserted-by":"crossref","unstructured":"Grothey A, Jordan K, Kellner O, Constantin C, Dietrich G, Kroening H, et al. Capecitabine\/irinotecan (Capiri) and capecitabine\/oxaliplatin (CapOx) are active second-line protocols in patients with advanced colorectal cancer (ACRC) after failure of first-line combination therapy: Results of a randomized phase II study. Proc Am Soc Clin Oncol 2004;23:254. [Abstr 3534].","DOI":"10.1200\/jco.2004.22.14_suppl.3534"},{"key":"key-10.4103\/0019-509X.237893-8","first-page":"1157","article-title":"Arsenic trioxide suppresses thymidylate synthase in 5-FU-resistant colorectal cancer cell line HT29 in vitro re-sensitizing cells to 5-FU","author":"Subbarayan","year":"2010","journal-title":"Anticancer Res"},{"key":"key-10.4103\/0019-509X.237893-9","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1158\/1078-0432.CCR-09-2590","article-title":"A phase I study of 5-fluorouracil\/leucovorin and arsenic trioxide for patients with refractory\/relapsed colorectal carcinoma","author":"Ardalan","year":"2010","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/0019-509X.237893-10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1593\/tlo.12322","article-title":"Arsenic trioxide as a vascular disrupting agent: Synergistic effect with irinotecan on tumor growth delay in a ct26 allograft model","author":"Lee","year":"2013","journal-title":"Transl Oncol"},{"key":"key-10.4103\/0019-509X.237893-11","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/S0959-8049(99)00150-1","article-title":"CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer.GERCOR","author":"Andr\u00e9","year":"1999","journal-title":"Eur J Cancer"},{"key":"key-10.4103\/0019-509X.237893-12","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1182\/blood.V94.10.3315.422k16_3315_3324","article-title":"Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: Remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients","author":"Niu","year":"1999","journal-title":"Blood"},{"key":"key-10.4103\/0019-509X.237893-13","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1158\/1535-7163.MCT-08-0595","article-title":"Arsenic trioxide is highly cytotoxic to small cell lung carcinoma cells","author":"Pettersson","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"key-10.4103\/0019-509X.237893-14","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1089\/thy.2008.0114","article-title":"Antitumor effects of arsenic trioxide in transformed human thyroid cells","author":"Fr\u00f6hlich","year":"2008","journal-title":"Thyroid"},{"key":"key-10.4103\/0019-509X.237893-15","first-page":"34","article-title":"Increased thymidylate synthase gene expression in liver metastases from colorectal carcinoma: Implications for chemotherapeutic options and survival","author":"Bathe","year":"1999","journal-title":"Cancer J Sci Am"},{"key":"key-10.4103\/0019-509X.237893-16","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/sj.tpj.6500469","article-title":"Transcription factor-binding sites in the thymidylate synthase gene: predictors of outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin?","author":"Par\u00e9","year":"2008","journal-title":"Pharmacogenomics J"},{"key":"key-10.4103\/0019-509X.237893-17","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1081\/CNV-200029068","article-title":"Arsenic trioxide causes redistribution of cell cycle, caspase activation, and GADD expression in human colonic, breast, and pancreatic cancer cells","author":"Li","year":"2004","journal-title":"Cancer Invest"},{"key":"key-10.4103\/0019-509X.237893-18","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1016\/S0024-3205(01)01545-4","article-title":"Arsenic trioxide-induced apoptosis through oxidative stress in cells of colon cancer cell lines","author":"Nakagawa","year":"2002","journal-title":"Life Sci"}],"container-title":["Indian Journal of Cancer"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:41:15Z","timestamp":1786732875000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijc.IJC_374_17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017]]}},"alternative-id":["237893"],"URL":"https:\/\/doi.org\/10.4103\/ijc.ijc_374_17","relation":{},"ISSN":["0019-509X"],"issn-type":[{"value":"0019-509X","type":"print"}],"subject":[],"published":{"date-parts":[[2017]]}}}